{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:28:01Z","timestamp":1787855281973,"version":"build-2784847793"},"reference-count":109,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cancer immunotherapy using immune-checkpoint inhibitors (ICI) has revolutionized the therapeutic landscape of various malignancies like non-small-cell lung cancer or melanoma. Pre-therapy response prediction and assessment during ICI treatment is challenging due to the lack of reliable biomarkers and the possibility of atypical radiological response patterns. Positron emission tomography\/computed tomography (PET\/CT) enables the visualization and quantification of metabolic lesion activity additional to conventional CT imaging. Various biomarkers derived from PET\/CT have been reported as predictors for response to ICI and may aid to overcome the challenges clinicians currently face in the management of ICI-treated patients. In this narrative review, experts in nuclear medicine, thoracic oncology, dermatooncology, hemato- and internal oncology, urological and head\/neck tumors performed literature reviews in their respective field and a joint discussion on the use of PET\/CT in the context of ICI treatment. The aims were to give a clinical overview on present standards and evidence, to identify current challenges and fields of research and to enable an outlook to future developments and their possible implications. Multiple promising studies concerning ICI response assessment or prediction using biomarkers derived from PET\/CT alone or as composite biomarkers have been identified for various malignancies and disease stages. Of interest, additional major incentives in the field may evolve from novel tracers specifically targeting immune-checkpoint molecules which could allow not only response assessment and prognosis, but also visualization of histological tumor cell properties like programmed death-ligand (PD-L1) expression in vivo. Despite the broad range of existing literature on PET\/CT-derived biomarkers in ICI therapy, implications for daily clinical practice remain elusive. High-quality prospective data are urgently warranted to determine whether patients benefit from the application of PET\/CT in terms of prognosis. At the moment, the lack of such evidence as well as the absence of standardized imaging methods and biomarkers still precludes PET\/CT imaging to be included in the relevant clinical practice guidelines.<\/jats:p>","DOI":"10.3390\/jcm9113483","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T23:06:12Z","timestamp":1604012772000},"page":"3483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Impact of PET\/CT for Assessing Response to Immunotherapy\u2014A Clinical Perspective"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3098-1554","authenticated-orcid":false,"given":"David","family":"Lang","sequence":"first","affiliation":[{"name":"Department of Pulmonology Johannes Kepler University Hospital Linz, Krankenhausstrasse 9, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wahl","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Johannes Kepler University Hospital Linz, Krankenhausstrasse 9, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Poier","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Johannes Kepler University Hospital Linz, Krankenhausstrasse 9, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-5653","authenticated-orcid":false,"given":"Sebastian","family":"Graf","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology, Johannes Kepler University Hospital Linz Krankenhausstrasse 9, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-9494","authenticated-orcid":false,"given":"David","family":"Kiesl","sequence":"additional","affiliation":[{"name":"University Clinic of Hematology and Internal Oncology Johannes Kepler University Hospital Linz, Krankenhausstrasse 9, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Lamprecht","sequence":"additional","affiliation":[{"name":"Department of Pulmonology Johannes Kepler University Hospital Linz, Krankenhausstrasse 9, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Medicine and Endocrinology, Johannes Kepler University Hospital Linz, Krankenhausstrasse 9, 4020 Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00259-020-04702-4","article-title":"Evaluating response to immunotherapy with 18F-FDG PET\/CT: Where do we stand?","volume":"47","author":"Aide","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12766","article-title":"Immune checkpoint inhibitors: The linchpins of modern immunotherapy","volume":"290","author":"Wilky","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New Guidelines to Evaluate the Response to Treatment in Solid Tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_4","first-page":"1519","article-title":"Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study","volume":"45","author":"Boellaard","year":"2004","journal-title":"J. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00259-020-04792-0","article-title":"Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy","volume":"47","author":"Nakamoto","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lungcan.2016.01.024","article-title":"Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib","volume":"94","author":"Fledelius","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: Association with outcome and transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00259-018-4211-0","article-title":"Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in melanoma patients treated with ipilimumab therapy","volume":"46","author":"Ito","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jtho.2018.05.004","article-title":"FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1\u2013Selected Patients With NSCLC","volume":"13","author":"Spigel","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","article-title":"Metabolic activity by 18F\u2013FDG-PET\/CT is predictive of early response after nivolumab in previously treated NSCLC","volume":"45","author":"Kaira","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","article-title":"Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab","volume":"45","author":"Anwar","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20170457","DOI":"10.1259\/bjr.20170457","article-title":"Immune-related tumour response assessment criteria: a comprehensive review","volume":"91","author":"Somarouthu","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bcmd.2003.09.002","article-title":"Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation","volume":"32","author":"Fu","year":"2004","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2362.2007.01786.x","article-title":"Glucose transporter expression on the plasma membrane of resting and activated white blood cells","volume":"37","author":"Maratou","year":"2007","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Decazes, P., and Bohn, P. (2020). Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications. Cancers (Basel), 12.","DOI":"10.3390\/cancers12020371"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","article-title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","volume":"29","author":"Tan","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2967\/jnumed.119.234278","article-title":"Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of 18 F-FDG PET\/CT","volume":"61","author":"Iravani","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","article-title":"Evaluating tumor response with FDG PET: Updates on PERCIST, comparison with EORTC criteria and clues to future developments","volume":"44","author":"Pinker","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2967\/jnumed.114.148056","article-title":"Quantitative PET\/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom","volume":"56","author":"Sunderland","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.109.074104","article-title":"Variations in PET\/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team Survey","volume":"52","author":"Graham","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s00259-019-04573-4","article-title":"18FDG PET\/CT in the early assessment of non-small cell lung cancer response to immunotherapy: Frequency and clinical significance of atypical evolutive patterns","volume":"47","author":"Humbert","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive Disease in Patients With Advanced Non\u2013Small Cell Lung Cancer Treated With PD-1\/PD-L1 Inhibitors or With Single-Agent Chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","article-title":"Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: Introduction of iPERCIST","volume":"9","author":"Goldfarb","year":"2019","journal-title":"EJNMMI Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","article-title":"Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET\/CT Imaging in Patients with Advanced Melanoma","volume":"58","author":"Cho","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2967\/jnumed.118.213652","article-title":"18 F-FDG PET\/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma","volume":"60","author":"Ito","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2967\/jnumed.119.232827","article-title":"Early 18 F-FDG PET\/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab","volume":"61","author":"Chen","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy","volume":"46","author":"Aide","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00262-018-2279-9","article-title":"Can benign lymphoid tissue changes in 18F-FDG PET\/CT predict response to immunotherapy in metastatic melanoma?","volume":"68","author":"Sachpekidis","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CMR.0000000000000541","article-title":"18F-FDG PET\/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab","volume":"29","author":"Sachpekidis","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","article-title":"Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET\/CT","volume":"44","author":"Nobashi","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1055\/a-1140-5458","article-title":"Textural features in FDG-PET\/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab","volume":"59","author":"Dittrich","year":"2020","journal-title":"Nuklearmedizin"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00259-019-04348-x","article-title":"18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer","volume":"46","author":"Jreige","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Laura, E., Sepulcri, M., and Pasello, G. (2019). PET\/CT And The Response To Immunotherapy In Lung Cancer. Curr. Radiopharm., 13.","DOI":"10.2174\/1874471013666191220105449"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.119.229781","article-title":"First-in-Humans Imaging with 89 Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting","volume":"61","author":"Postow","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbrc.2016.12.156","article-title":"Rapid PD-L1 detection in tumors with PET using a highly specific peptide","volume":"483","author":"Chatterjee","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"153601211985218","DOI":"10.1177\/1536012119852189","article-title":"Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide","volume":"18","author":"Lesniak","year":"2019","journal-title":"Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI122216","article-title":"Peptide-based PET quantifies target engagement of PD-L1 therapeutics","volume":"129","author":"Kumar","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN Guidelines Insights: Non\u2013Small Cell Lung Cancer, Version 1.2020","volume":"17","author":"Ettinger","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.6004\/jnccn.2018.0079","article-title":"NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018","volume":"16","author":"Kalemkerian","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Popat","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/RLU.0000000000001886","article-title":"Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET\/CT as Prognostic Markers in Non\u2013Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy","volume":"43","author":"Sharma","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hashimoto, K., Kaira, K., Yamaguchi, O., Mouri, A., Shiono, A., Miura, Y., Murayama, Y., Kobayashi, K., Kagamu, H., and Kuji, I. (2020). Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030725"},{"key":"ref_58","first-page":"7073","article-title":"Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET\/CT in Patients with Small-sized Lung Cancer","volume":"37","author":"Takada","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/MNM.0000000000001025","article-title":"18F-FDG PET\/CT in non-small-cell lung cancer patients","volume":"40","author":"Evangelista","year":"2019","journal-title":"Nucl. Med. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13362","DOI":"10.1038\/s41598-019-50079-2","article-title":"18F-FDG uptake in PET\/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer","volume":"9","author":"Takada","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cpet.2019.08.009","article-title":"18F-Fluorodeoxyglucose PET in Locally Advanced Non\u2013small Cell Lung Cancer","volume":"15","author":"Brodin","year":"2020","journal-title":"PET Clin."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2967\/jnumed.119.237768","article-title":"Hyperprogressive Disease in Patients with Non\u2013Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18 F-FDG PET\/CT","volume":"61","author":"Castello","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00432-020-03150-9","article-title":"The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors","volume":"146","author":"Castello","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2967\/jnmt.117.204933","article-title":"18 F-FDG PET\/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer","volume":"46","author":"Eshghi","year":"2018","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00262-018-2229-6","article-title":"Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET\u2013CT","volume":"68","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients with Advanced Melanoma Treated with Pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00259-020-04826-7","article-title":"Metastatic melanoma: Can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?","volume":"47","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","article-title":"Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4","volume":"47","author":"Seban","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","article-title":"18F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma","volume":"20","author":"Wong","year":"2020","journal-title":"Cancer Imaging"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ayati, N., Sadeghi, R., Kiamanesh, Z., Lee, S.T., Zakavi, S.R., and Scott, A.M. (2020). The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging.","DOI":"10.1007\/s00259-020-04967-9"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","article-title":"FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment","volume":"47","author":"Iravani","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1634\/theoncologist.2018-0686","article-title":"Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1\/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer","volume":"24","author":"Winer","year":"2019","journal-title":"Oncologist"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Vera, D.R.B., Smith, C.C., Bixby, L.M., Glatt, D.M., Dunn, S.S., Saito, R., Kim, W.Y., Serody, J.S., Vincent, B.G., and Parrott, M.C. (2018). Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193832"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","article-title":"Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma","volume":"12","author":"Wang","year":"2012","journal-title":"Cancer Imaging"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1097\/01.ju.0000120241.50061.e4","article-title":"Clinical Use of Fluorodeoxyglucose F 18 Positron Emission Tomography for Detection of Renal Cell Carcinoma","volume":"171","author":"Kang","year":"2004","journal-title":"J. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s00259-003-1211-4","article-title":"Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT","volume":"30","author":"Aide","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU Guidelines on Renal Cell Carcinoma: 2014 Update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/1450-1147.150535","article-title":"Clinical Effectiveness of 18F-Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Management of Renal Cell Carcinoma: A Single Institution Experience","volume":"14","author":"Win","year":"2015","journal-title":"World J. Nucl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Namura, K., Minamimoto, R., Yao, M., Makiyama, K., Murakami, T., Sano, F., Hayashi, N., Tateishi, U., Ishigaki, H., and Kishida, T. (2010). Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography (18F-FDG-PET\/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-667"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s13139-013-0245-1","article-title":"Can Initial 18F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma?","volume":"48","author":"Lee","year":"2013","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_83","first-page":"2665","article-title":"18F-FDG-PET\/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation","volume":"33","author":"Ferda","year":"2013","journal-title":"Anticancer. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2018.04.026","article-title":"Positron Emission Tomography\/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion","volume":"74","author":"Hekman","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fonc.2019.00884","article-title":"Past, Current, and Future of Immunotherapies for Prostate Cancer","volume":"9","author":"Boettcher","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ucl.2020.07.008","article-title":"Immunotherapy for Localized Prostate Cancer","volume":"47","author":"Patel","year":"2020","journal-title":"Urol. Clin. N. Am."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Evangelista, L., Zattoni, F., Cassarino, G., Artioli, P., Cecchin, D., Moro, F.D., and Zucchetta, P. (2020). PET\/MRI in prostate cancer: a systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging, 1\u201315.","DOI":"10.1007\/s00259-020-05025-0"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JU.0000000000000531","article-title":"Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography\/Computerized Tomography for Primary Staging of Prostate Cancer","volume":"203","author":"Lavalaye","year":"2020","journal-title":"J. Urol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, Specificity, and Predictors of Positive 68 Ga\u2013Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3390\/cancers6041821","article-title":"Positron Emission Tomography (PET) in Oncology","volume":"6","author":"Gallamini","year":"2014","journal-title":"Cancers"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1148\/radiol.2020192056","article-title":"Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma","volume":"295","author":"Mokrane","year":"2020","journal-title":"Radiology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"20160217","DOI":"10.1259\/bjr.20160217","article-title":"Role of fluorine-18 fluorodeoxyglucose PET\/CT in head and neck oncology: The point of view of the radiation oncologist","volume":"89","author":"Cacicedo","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0360-3016(01)01690-X","article-title":"Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer","volume":"51","author":"Ang","year":"2001","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2002.02.590","article-title":"Diagnostic and Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma","volume":"20","author":"Wong","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijrobp.2008.07.019","article-title":"Clinical Significance of Postradiotherapy [18F]-Fluorodeoxyglucose Positron Emission Tomography Imaging in Management of Head-and-Neck Cancer\u2014A Long-Term Outcome Report","volume":"74","author":"Yao","year":"2009","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_101","first-page":"640","article-title":"A Descriptive, Longitudinal Study of Quality of Life and Perceived Health Needs in Patients With Head and Neck Cancer","volume":"7","author":"Sandstrom","year":"2016","journal-title":"J. Adv. Pr. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oraloncology.2019.04.025","article-title":"Upfront PET\/CT affects management decisions in patients with recurrent head and neck squamous cell carcinoma","volume":"94","author":"Rohde","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","article-title":"PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer","volume":"374","author":"Mehanna","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1200\/JCO.2020.38.15_suppl.3573","article-title":"89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck","volume":"38","author":"Verhoeff","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"117955492095054","DOI":"10.1177\/1179554920950548","article-title":"Results of the Austrian National Lung Cancer Audit","volume":"14","author":"Burghuber","year":"2020","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non\u2013Small-Cell Lung Cancer","volume":"379","author":"Luft","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:30:10Z","timestamp":1760178610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":109,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["jcm9113483"],"URL":"https:\/\/doi.org\/10.3390\/jcm9113483","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]}}}